<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39056206</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Fecal microbiota transplantation alleviates mild-moderate COVID-19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double-blind clinical trial.</ArticleTitle><Pagination><StartPage>e29812</StartPage><MedlinePgn>e29812</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29812</ELocationID><Abstract><AbstractText>Currently, the emergence of the endemic Coronavirus disease (COVID-19) situation still poses a serious threat to public health. However, it remains elusive about the role of fecal microbiota transplantation in treating COVID-19. We performed a randomized, double-blind, placebo-controlled clinical trial enrolling a cohort of 40 COVID-19 patients with mild-moderate symptoms. Our results showed that fecal microbiota transplantation provided an amelioration in diarrhoea (p&#x2009;=&#x2009;0.026) of digestive system and depression (p&#x2009;=&#x2009;0.006) of neuropsychiatric-related symptom in COVID-19 patients, respectively. Meanwhile, we found that the number of patients with diarrhoea decreased from 19 to 0 on day 7 after fecal microbiota transplantation treatment, and it was statistically changed compared to the placebo group (p&#x2009;=&#x2009;0.047). Of note, the serum concentration of aspartate aminotransferase-to-alanine aminotransferase ratio (AST/ALT, fecal microbiota transplantation, pre vs. post: 0.966 vs. 0.817), a biomarker for predicting long COVID-19, was significantly reduced by fecal microbiota transplantation. In all, our study supports that fecal microbiota transplantation could be a novel therapeutic strategy for COVID-19 patients with diarrhoea and depressive symptoms, which is potentially valuable in ameliorating long COVID-19 symptoms.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jiaqi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>Yongbin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Physical Examination Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zifeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zibin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chengyang</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5523-8169</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Da</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Fu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Feifan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chengcheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhongxin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zengren</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-4802-3581</Identifier><AffiliationInfo><Affiliation>Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Construction Funds of Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment from The First Hospital of Hebei Medical University; and other Hebei Province Projects</Agency><Country/></Grant><Grant><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><Agency>The Natural Science Foundation of Hebei</Agency><Country/></Grant><Grant><Agency>Hebei Provincial Department of Human Resources and Social Security</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.6.1.1</RegistryNumber><NameOfSubstance UI="D001219">Aspartate Aminotransferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069467" MajorTopicYN="Y">Fecal Microbiota Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="Y">Diarrhea</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001219" MajorTopicYN="N">Aspartate Aminotransferases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AST/ALT</Keyword><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">diarrhoea</Keyword><Keyword MajorTopicYN="N">fecal microbiota transplantation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39056206</ArticleId><ArticleId IdType="doi">10.1002/jmv.29812</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Rathinasamy M, Kandhasamy S. An exploratory study on the propagation of SARS&#x2010;CoV&#x2010;2 variants: omicron is the most predominant variant. J Med Virol. 2022;94:2414&#x2010;2421.</Citation></Reference><Reference><Citation>Li Y, Zhang Z, Du XQ, et al. Variation characteristics of COVID&#x2010;19 omicron variant and its impact on immunological properties (in Chinese). Int J Immunol. 2022;45:1&#x2010;4.</Citation></Reference><Reference><Citation>Montani D, Savale L, Noel N, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Eur Respir Rev. 2022;31:210185.</Citation></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID&#x2010;19. JAMA. 2020;324:603&#x2010;605.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2010;146.</Citation></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, et al. Gut microbiota dynamics in a prospective cohort of patients with post&#x2010;acute COVID&#x2010;19 syndrome. Gut. 2022;71(3):544&#x2010;552.</Citation></Reference><Reference><Citation>Meringer H, Mehandru S. Gastrointestinal post&#x2010;acute COVID&#x2010;19 syndrome. Nat Rev Gastroenterol Hepatol. 2022;19(6):345&#x2010;346.</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. RETRACTED: 6&#x2010;month consequences of COVID&#x2010;19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220&#x2010;232.</Citation></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID&#x2010;19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x2010;1198.</Citation></Reference><Reference><Citation>Gulati AS, Nicholson MR, Khoruts A, Kahn SA. Fecal microbiota transplantation across the lifespan: balancing efficacy, safety, and innovation. Am J Gastroenterol. 2023;118:435&#x2010;439.</Citation></Reference><Reference><Citation>Antushevich H. Fecal microbiota transplantation in disease therapy. Clin Chim Acta. 2020;503:90&#x2010;98.</Citation></Reference><Reference><Citation>De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis: the transaminase serum activities. Clin Chim Acta. 1957;2:70&#x2010;74.</Citation></Reference><Reference><Citation>Zinellu A, Arru F, De Vito A, et al. The De Ritis ratio as prognostic biomarker of in&#x2010;hospital mortality in COVID&#x2010;19 patients. Eur J Clin Invest. 2021;51:e13427.</Citation></Reference><Reference><Citation>Pranata R, Huang I, Lim MA, et al. Elevated De Ritis ratio is associated with poor prognosis in COVID&#x2010;19: a systematic review and meta&#x2010;analysis. Front Med. 2021;8:676581.</Citation></Reference><Reference><Citation>Li C, Ta LX, Zhang XM, et al. Introduction to the European consensus on fecal transplantation in 2016 (in Chinese). Chin J Gastroenterol Hepatol. 2017;26:961&#x2010;965.</Citation></Reference><Reference><Citation>Liu F, Ye S, Zhu X, et al. Gastrointestinal disturbance and effect of fecal microbiota transplantation in discharged COVID&#x2010;19 patients. J Med Case Reports. 2021;15:60.</Citation></Reference><Reference><Citation>Shen Z, Zhu C, Quan Y, et al. Update on intestinal microbiota in Crohn's disease 2017: mechanisms, clinical application, adverse reactions, and outlook. J Gastroenterol Hepatol. 2017;32:1804&#x2010;1812.</Citation></Reference><Reference><Citation>Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID&#x2010;19 and other coronaviruses. Brain Behav Immun. 2020;87:18&#x2010;22.</Citation></Reference><Reference><Citation>Boldrini M, Canoll PD, Klein RS. How COVID&#x2010;19 affects the brain. JAMA Psychiatry. 2021;78(6):682&#x2010;683.</Citation></Reference><Reference><Citation>Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS&#x2010;CoV&#x2010;2 in human and mouse brain. J Exp Med. 2021;218(3):e20202135.</Citation></Reference><Reference><Citation>Rhea EM, Logsdon AF, Hansen KM, et al. The S1 protein of SARS&#x2010;CoV&#x2010;2 crosses the blood&#x2010;brain barrier in mice. Nature Neurosci. 2021;24(3):368&#x2010;378.</Citation></Reference><Reference><Citation>Hashimoto K. Detrimental effects of COVID&#x2010;19 in the brain and therapeutic options for long COVID: the role of Epstein&#x2010;Barr virus and the gut&#x2010;brain axis. Mol Psychiatry. 2023;28:4968&#x2010;4976.</Citation></Reference><Reference><Citation>Wang B, Zhang L, Wang Y, et al. Alterations in microbiota of patients with COVID&#x2010;19: potential mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022;7:143.</Citation></Reference><Reference><Citation>Lei HY, Ding YH, Nie K, et al. Potential effects of SARS&#x2010;CoV&#x2010;2 on the gastrointestinal tract and liver. Biomed Pharmacother. 2021;133:111064.</Citation></Reference><Reference><Citation>Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID&#x2010;19 during time of hospitalization. Gastroenterology. 2020;159:944&#x2010;955.e8.</Citation></Reference><Reference><Citation>Khanna S, Tande A, Rubin DT, Khoruts A, Kahn SA, Pardi DS. Fecal microbiota transplantation for recurrent C difficile infection during the COVID&#x2010;19 pandemic. Mayo Clin Proc. 2021;96(6):1418&#x2010;1425.</Citation></Reference><Reference><Citation>Barberio B, Massimi D, Bonfante L, et al. Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. Therap Adv Gastroenterol. 2020;13:1756284820934589.</Citation></Reference><Reference><Citation>Hammond J, Leister&#x2010;Tebbe H, Gardner A, et al. Oral Nirmatrelvir for high&#x2010;risk, nonhospitalized adults with Covid&#x2010;19. N Engl J Med. 2022;386:1397&#x2010;1408.</Citation></Reference><Reference><Citation>Li N, Wang Q, Wang Y, et al. Fecal microbiota transplantation from chronic unpredictable mild stress mice donors affects anxiety&#x2010;like and depression&#x2010;like behavior in recipient mice via the gut microbiota&#x2010;inflammation&#x2010;brain axis. Stress. 2019;22:592&#x2010;602.</Citation></Reference><Reference><Citation>Sonali S, Ray B, Ahmed Tousif H, et al. Mechanistic insights into the link between gut dysbiosis and major depression: an extensive review. Cells. 2022;11:1362.</Citation></Reference><Reference><Citation>Fond GB, Lagier JC, Honore S, et al. Microbiota&#x2010;orientated treatments for major depression and schizophrenia. Nutrients. 2020;12:1024.</Citation></Reference><Reference><Citation>Allegretti JR, Allegretti AS, Phelps E, Xu H, Fischer M, Kassam Z. Classifying fecal microbiota transplantation failure: an observational study examining timing and characteristics of fecal microbiota transplantation failures. Clin Gastroenterol Hepatol. 2018;16:1832&#x2010;1833.</Citation></Reference><Reference><Citation>Li Q, Ding X, Liu K, et al. Fecal microbiota transplantation for ulcerative colitis: the optimum timing and gut microbiota as predictors for long&#x2010;term clinical outcomes. Clin Transl Gastroenterol. 2020;11:e00224.</Citation></Reference><Reference><Citation>Nejadghaderi SA, Nazemalhosseini&#x2010;Mojarad E, Asadzadeh Aghdaei H. Fecal microbiota transplantation for COVID&#x2010;19; a potential emerging treatment strategy. Med Hypotheses. 2021;147:110476.</Citation></Reference><Reference><Citation>*He J, He X, Ma Y, et al. A comprehensive approach to stool donor screening for faecal microbiota transplantation in China. Microb Cell Fact. 2021;20(1):216.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>